JP2024520674A5 - - Google Patents
Info
- Publication number
- JP2024520674A5 JP2024520674A5 JP2023574472A JP2023574472A JP2024520674A5 JP 2024520674 A5 JP2024520674 A5 JP 2024520674A5 JP 2023574472 A JP2023574472 A JP 2023574472A JP 2023574472 A JP2023574472 A JP 2023574472A JP 2024520674 A5 JP2024520674 A5 JP 2024520674A5
- Authority
- JP
- Japan
- Prior art keywords
- group
- ch2ch2o
- iii
- pharmaceutically acceptable
- heterocyclyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (11)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNPCT/CN2021/098024 | 2021-06-02 | ||
| CN2021098024 | 2021-06-02 | ||
| CN202110651300 | 2021-06-10 | ||
| CN202110651300.6 | 2021-06-10 | ||
| CN202111198590.X | 2021-10-14 | ||
| CN202111198590 | 2021-10-14 | ||
| CN202111595515.7 | 2021-12-23 | ||
| CN202111595515 | 2021-12-23 | ||
| CN202111602429.4 | 2021-12-24 | ||
| CN202111602429 | 2021-12-24 | ||
| PCT/CN2022/096690 WO2022253284A1 (zh) | 2021-06-02 | 2022-06-01 | 药物偶联物及其用途 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024520674A JP2024520674A (ja) | 2024-05-24 |
| JP2024520674A5 true JP2024520674A5 (https=) | 2025-06-06 |
Family
ID=84240734
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023574472A Pending JP2024520674A (ja) | 2021-06-02 | 2022-06-01 | 薬物コンジュゲート及びその使用 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20240269315A1 (https=) |
| EP (1) | EP4349371A4 (https=) |
| JP (1) | JP2024520674A (https=) |
| CN (2) | CN117295524A (https=) |
| WO (1) | WO2022253284A1 (https=) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20250262316A1 (en) * | 2021-10-14 | 2025-08-21 | Bio-Thera Solutions, Ltd. | Antibody-drug conjugate and application thereof |
| US11814394B2 (en) | 2021-11-16 | 2023-11-14 | Genequantum Healthcare (Suzhou) Co., Ltd. | Exatecan derivatives, linker-payloads, and conjugates and thereof |
| US20250059274A1 (en) * | 2021-12-24 | 2025-02-20 | Bio-Thera Solutions, Ltd. | ANTI-FRa ANTIBODY, AND ANTIBODY-DRUG CONJUGATE AND USE THEREOF |
| EP4509141A1 (en) * | 2022-04-12 | 2025-02-19 | Bio-Thera Solutions, Ltd. | Method for treating her2-positive solid tumor |
| CN117143237A (zh) * | 2022-06-01 | 2023-12-01 | 百奥泰生物制药股份有限公司 | 抗cldn18.2抗体及其抗体药物偶联物和用途 |
| WO2024012541A1 (zh) * | 2022-07-14 | 2024-01-18 | 百奥泰生物制药股份有限公司 | 抗Nectin-4抗体药物偶联物及应用 |
| IL318296A (en) | 2022-07-15 | 2025-03-01 | Genequantum Healthcare Suzhou Co Ltd | Anti-TROP2 antibody and its conjugate |
| JP2026503204A (ja) * | 2023-01-09 | 2026-01-28 | スーチュアン・コールン－バイオテック・バイオファーマシューティカル・カンパニー・リミテッド | 窒素含有縮合環化合物の調製方法 |
| TW202502774A (zh) * | 2023-03-01 | 2025-01-16 | 大陸商江蘇恆瑞醫藥股份有限公司 | 一種茚并［１，２－ｂ］喹啉－１０，１３－二酮衍生物的製備方法 |
| WO2025002310A1 (zh) * | 2023-06-29 | 2025-01-02 | 石药集团巨石生物制药有限公司 | 抗体-药物偶联物及其用途 |
| WO2025036307A1 (zh) * | 2023-08-11 | 2025-02-20 | 百奥泰生物制药股份有限公司 | 抗frα抗体药物偶联物在治疗疾病中的应用 |
| WO2025106278A1 (en) | 2023-11-17 | 2025-05-22 | Mersana Therapeutics, Inc. | Treatment of cancer using b7-h4-targeted antibody-drug conjugates |
| WO2025153092A1 (en) * | 2024-01-18 | 2025-07-24 | Beijing Joinn Biologics Co., Ltd | Antibody-drug conjugate |
| WO2025190251A1 (zh) * | 2024-03-12 | 2025-09-18 | 百奥泰生物制药股份有限公司 | 抗trop2抗体药物偶联物和pd-1拮抗剂联合治疗实体瘤的用途 |
| WO2025190255A1 (zh) * | 2024-03-12 | 2025-09-18 | 百奥泰生物制药股份有限公司 | 治疗宫颈癌、胸腺肿瘤或激素受体阳性和her2阴性乳腺癌的方法 |
| WO2025190318A1 (zh) * | 2024-03-13 | 2025-09-18 | 百奥泰生物制药股份有限公司 | 抗her2抗体药物偶联物和her二聚化抑制剂联合治疗实体瘤 |
| CN120837674A (zh) * | 2024-04-28 | 2025-10-28 | 百奥泰生物制药股份有限公司 | 抗Nectin-4抗体药物偶联物治疗肿瘤的方法 |
| CN120919340A (zh) * | 2024-05-09 | 2025-11-11 | 百奥泰生物制药股份有限公司 | 抗FRα抗体药物偶联物和PD-1拮抗剂在治疗肿瘤中的应用 |
| CN121015902A (zh) * | 2024-05-27 | 2025-11-28 | 百奥泰生物制药股份有限公司 | 抗trop2抗体药物偶联物和抗pd-l1/cd47双特异抗体联合治疗肿瘤的用途 |
| CN121015903A (zh) * | 2024-05-27 | 2025-11-28 | 百奥泰生物制药股份有限公司 | 抗trop2抗体药物偶联物和vegf-a抑制剂联合治疗肿瘤的用途 |
| WO2026002234A1 (zh) * | 2024-06-29 | 2026-01-02 | 百奥泰生物制药股份有限公司 | 药物偶联物及其制备方法和用途 |
| CN121606577A (zh) * | 2024-08-27 | 2026-03-06 | 百奥泰生物制药股份有限公司 | 抗FRα抗体药物偶联物和VEGF拮抗剂在治疗肿瘤中的应用 |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0856054B1 (en) | 1995-10-19 | 2004-04-28 | Bristol-Myers Squibb Company | Monoclonal antibody br110 and uses thereof |
| CA2478047C (en) | 2002-03-01 | 2014-01-21 | Immunomedics, Inc. | Rs7 antibodies |
| EP1790664A1 (en) | 2005-11-24 | 2007-05-30 | Ganymed Pharmaceuticals AG | Monoclonal antibodies against claudin-18 for treatment of cancer |
| EA201500220A1 (ru) | 2010-05-17 | 2015-10-30 | Ливтех, Инк. | Антитело против trop-2 человека, обладающее противоопухолевой активностью in vivo |
| WO2011155579A1 (ja) | 2010-06-10 | 2011-12-15 | 北海道公立大学法人札幌医科大学 | 抗Ｔｒｏｐ－２抗体 |
| TWI495644B (zh) | 2011-11-11 | 2015-08-11 | Rinat Neuroscience Corp | 營養層細胞表面抗原（Ｔｒｏｐ－２）之專一性抗體類及彼等之用途 |
| US9931417B2 (en) | 2012-12-13 | 2018-04-03 | Immunomedics, Inc. | Antibody-SN-38 immunoconjugates with a CL2A linker |
| AU2014371934B2 (en) | 2013-12-25 | 2020-01-23 | Daiichi Sankyo Company, Limited | Anti-TROP2 antibody-drug conjugate |
| PE20231050A1 (es) * | 2016-03-02 | 2023-07-11 | Eisai Randd Man Co Ltd | Conjugados de anticuerpo y farmaco basados en eribulina y metodos para su uso |
| US20210093733A1 (en) * | 2016-11-21 | 2021-04-01 | Obi Pharma, Inc. | Conjugated biological molecules, pharmaceutical compositions and methods |
| BR112020020466A2 (pt) * | 2018-04-06 | 2021-01-12 | Seattle Genetics, Inc. | Conjugados de peptídeo de camptotecina |
| TW202016081A (zh) * | 2018-06-21 | 2020-05-01 | 英商克拉德夫製藥有限公司 | 人類ｓｔｉｎｇ之小分子調節劑、結合物及治療應用 |
| KR20210050547A (ko) | 2018-08-27 | 2021-05-07 | 난징 산홈 팔마세우티칼 컴퍼니 리미티드 | 항-클라우딘18.2 항체 및 이의 용도 |
| CN110903395A (zh) | 2018-09-14 | 2020-03-24 | 四川科伦博泰生物医药股份有限公司 | 抗体、偶联物及其制备方法和用途 |
| EP3872093A4 (en) | 2018-10-22 | 2022-10-19 | Shanghai Genbase Biotechnology Co., Ltd. | ANTI-CLDN18.2 ANTIBODIES AND USES THEREOF |
| CN113260384A (zh) * | 2018-11-05 | 2021-08-13 | 西纳福克斯股份有限公司 | 用于靶向表达trop-2的肿瘤的抗体缀合物 |
| CA3085001C (en) * | 2019-05-20 | 2021-10-05 | Mabplex International, Ltd. | One-pot process for preparing intermediate of antibody-drug conjugate |
| CN113853219B (zh) * | 2019-05-20 | 2025-01-07 | 诺华股份有限公司 | 具有包含亲水性基团的接头的抗体药物缀合物 |
| US20230030674A1 (en) | 2019-12-06 | 2023-02-02 | Sotio Biotech A.S. | Humanized cldn18.2 antibodies |
| JP7781064B2 (ja) | 2020-01-22 | 2025-12-05 | 江蘇恒瑞医薬股▲ふん▼有限公司 | 抗ｔｒｏｐ－２抗体－エキサテカン類似体複合体及びその医薬用途 |
| AU2021220887B2 (en) | 2020-02-10 | 2024-11-21 | Shanghai Escugen Biotechnology Co., Ltd. | CLDN18.2 antibody and use thereof |
| WO2021238831A1 (en) | 2020-05-25 | 2021-12-02 | Mabspace Biosciences (Suzhou) Co., Limited | Anti-cldn18.2 antibodies and diagnostic uses thereof |
| CN116589587A (zh) | 2020-06-22 | 2023-08-15 | 四川百利药业有限责任公司 | 一种抗trop2抗体 |
-
2022
- 2022-06-01 CN CN202280032877.1A patent/CN117295524A/zh active Pending
- 2022-06-01 JP JP2023574472A patent/JP2024520674A/ja active Pending
- 2022-06-01 CN CN202210617443.XA patent/CN115429893A/zh active Pending
- 2022-06-01 WO PCT/CN2022/096690 patent/WO2022253284A1/zh not_active Ceased
- 2022-06-01 EP EP22815326.8A patent/EP4349371A4/en active Pending
- 2022-06-01 US US18/566,371 patent/US20240269315A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024520674A5 (https=) | ||
| JP2024547111A5 (https=) | ||
| AU2018267660B2 (en) | Compounds and methods for the treatment of TROP2 positive diseases | |
| CN103269712B (zh) | 包含新型安丝菌素衍生物的细胞毒性剂 | |
| US8900589B2 (en) | Anthracycline derivative conjugates, process for their preparation and their use as antitumor compounds | |
| US8841425B2 (en) | Cytotoxic agents comprising new maytansinoids | |
| CN103288957B (zh) | 一种抑制肿瘤生长的抗体药物衍生物及其制备方法和用途 | |
| HRP20130953T1 (hr) | Pirolobenzodiazepini i njihovi konjugati | |
| CN1816356A (zh) | 药物缀合物组合物 | |
| CA2525130A1 (en) | Improved cytotoxic agents comprising new maytansinoids | |
| US20250249114A1 (en) | Method for treating her2-positive solid tumor | |
| CN102731611A (zh) | 细霉素衍生物 | |
| CN119421724A (zh) | 治疗实体瘤的方法 | |
| IL319611A (en) | Linker for antibody-drug conjugate and use thereof | |
| WO2025190255A1 (zh) | 治疗宫颈癌、胸腺肿瘤或激素受体阳性和her2阴性乳腺癌的方法 | |
| CN120837674A (zh) | 抗Nectin-4抗体药物偶联物治疗肿瘤的方法 | |
| RU2021100554A (ru) | Линкер для конъюгатов антитело-лекарственное средство и их применение | |
| CN121941512A (zh) | 稠环化合物及其制备方法和用途 | |
| CN119454999A (zh) | 抗FRα抗体药物偶联物在治疗疾病中的应用 | |
| CN119899238A (zh) | 稠环化合物及其制备方法和用途 | |
| HK1092730A (en) | Drug conjugate composition | |
| HK1175787A (en) | Leptomycin derivatives |